Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma

Published:2022-02-21 Issue:2 Volume:63 Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Pennington Thomas E¹²³^ORCID,Zhao Cathy Yunjia⁴^ORCID,Colebatch Andrew J¹²³⁵⁶,Fernandez‐Peñas Pablo²⁴,Guitera Pascale¹²³,Burke Hazel¹,Scolyer Richard A¹²⁵⁶,Menzies Alexander M¹²⁷,Carlino Matteo S¹²⁴,Lo Serigne¹²,Long Georgina V¹²⁷,Saw Robyn PM¹²³

Affiliation:

1. Melanoma Institute Australia The University of Sydney Sydney NSW Australia

2. Faculty of Medicine and Health The University of Sydney Sydney NSW Australia

3. Royal Prince Alfred Hospital Camperdown NSW Australia

4. Westmead Hospital Westmead New South Wales Australia

5. Department of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital Sydney NSW Australia

6. New South Wales Health Pathology Sydney NSW Australia

7. Royal North Shore Hospital Sydney NSW Australia

Funder

Melanoma Institute Australia

National Health and Medical Research Council

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.13807

Reference17 articles.

1. The incidence of second primary invasive melanoma in Queensland, 1982–2003

2. Distribution of Subsequent Primary Invasive Melanomas Following a First Primary Invasive or In Situ Melanoma in Queensland, Australia, 1982-2010

3. Multiple primary melanomas

4. Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma

5. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas;Frontiers in Oncology;2023-12-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3